Spectral today issued $6.3 million aggregate principal amount of 2026 Notes in the second tranche of the Offering. Together with the $7.7 million aggregate principal amount of 2026 Notes issued in the ...

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB.

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on December 4, 2026, to ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced interim safety and efficacy results from the VICTORIA-01 Phase 1 clinical study of SOT201, a PD-1 ...

PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, ...

Completion of the consultation process does not constitute regulatory approval. The CardiAMP Cell Therapy System remains subject to PMDA review and applicable Japanese regulatory requirements.

Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, ...

SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company ...

The presentations highlight BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform and BriaPro’s BP-80 and TILsRx immunotherapy programs, including advances in engineered CD80 proteins.

PrTK05 data show transient detection of aglatimagene vector DNA in peripheral blood after intraprostatic administration of aglatimagene and clearance in urine samples at weeks 16-18. These findings ...

Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW episode.

Modular platform enables dual-antigen targeting to limit tumor escape and performance-enhancing peptide armoring to improve solid tumor control Findings further support the potential of precise, ...